Drugs / AAV2-hCHM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02341807 | Jan 2015 → Oct 2022 | choroideremia | Spark Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV2-hCHM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02341807 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “recombinant adeno-associated virus serotype 2 (AAV2) vector” PMID 35714735 ↗ Jun 2022 |
| Route | Other | “subretinal administration of AAV2-hCHM” NCT02341807 ↗ |
| Target | CHM | “a human CHM-encoding cDNA (AAV2-hCHM)” PMID 35714735 ↗ Jun 2022 |